The global animal model market size was valued at USD 2.91 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.99 billion by 2034, registering a CAGR of 8.36% during the forecast period from 2026 to 2034. North America dominated the animal model market with a market share of 41.8% in 2025.
Animal models are living animals used in biomedical research to study biological processes, diseases, drug efficacy, safety, and potential therapeutic approaches. Common models include mice, rats, rabbits, zebrafish, and other laboratory animals selected according to research requirements. Animal models help researchers understand disease mechanisms, evaluate experimental treatments, assess drug toxicity, and generate preclinical data before potential therapies advance to human clinical studies.
Download a Free Sample To learn more about this report,
Humanized Animal Models Improve Human Immune-System Representation
Animal model market analysis shows that the need for more human-relevant preclinical results is shifting animal models toward genetically engineered systems that reproduce key components of the human immune system. A 2026 study developed humanized mice with syntenic replacement of disease-associated human NLRP3 variants and reproduced the clinical spectrum of cryopyrin-associated periodic syndromes across different disease severities. This transition improves the ability of animal models to reflect human genetic and immune mechanisms during disease research.
AI-Based Phenotyping Automates Behavioral and Disease Assessment
Complexity in measuring subtle disease-related changes is shifting animal research toward automated imaging and machine-learning-based phenotyping. A 2025 study used deep-learning models to analyze zebrafish with hypophosphatasia and enabled earlier detection of skeletal alterations through automated phenotype classification. This transition provides more consistent quantitative measurements while reducing dependence on manual observation during preclinical studies.
Preclinical Drug Development and Genetically Engineered Disease Models Drive Market
Pharmaceutical and biotechnology research creates sustained demand for animal models used to assess drug safety, efficacy, pharmacokinetics, and disease mechanisms before clinical trials. NIH’s 2025 animal-model program identifies improved in vivo models as important tools for preclinical therapeutic research. Oncology and cardiovascular drug programs, for example, use specialized mice and other laboratory animals to evaluate candidate therapies. This research activity supports demand for standardized animals and study-ready disease models.
Genetically engineered animals allow researchers to reproduce specific mutations and disease pathways that conventional models may not capture accurately. NIH’s 2025 program supports the development and characterization of improved animal models for human diseases and conditions. Applications in oncology and rare-disease research create demand for customized strains with defined genetic characteristics. This specialization expands demand for model development, breeding, and related animal-model services.
Stringent Animal Welfare Regulations and High Housing and Maintenance Costs Restrain Market Expansion
Strict animal-welfare requirements can add ethical reviews, documentation, facility standards, and institutional oversight to animal-based studies. These requirements can lengthen study preparation and increase compliance resources for pharmaceutical companies, CROs, and research institutions. Higher regulatory effort can slow adoption of animal models, particularly for smaller research organizations.
Specialized housing, veterinary care, controlled environments, feed, and breeding requirements create recurring expenses for animal research programs. These costs can reduce the number of animals and studies that research organizations can support within fixed budgets. Higher operating expenses can therefore restrict adoption of specialized animal models and constrain market expansion.
Veterinary Drug Development and Vaccine Research Offer Growth Opportunities
Veterinary pharmaceutical companies, animal-health firms, and CROs can use animal models for safety, pharmacokinetic, and efficacy studies of veterinary medicines. Charles River Laboratories provides research models and preclinical services that support animal-health research programs. Specialized testing packages and study-ready models create revenue through outsourced research services and recurring model supply, contributing to animal model market growth.
Vaccine developers, biotechnology companies, and research institutions can use rodents, nonhuman primates, and other models to assess vaccine safety and immune responses. Charles River supports infectious-disease and vaccine research through specialized animal models and related preclinical services. Model supply, breeding programs, and study-support services create additional revenue avenues for animal-model providers.
Specialized Animal Supply Constraints and Alternative Research Methods Hinder Growth
Highly specialized models, particularly nonhuman primates, can face supply constraints that affect study scheduling and procurement. NIH project documentation has reported acute shortages of research nonhuman primates following restrictions on Chinese exports and transport limitations, with acquisition costs rising substantially. Such supply disruptions can delay research programs and restrict revenue growth for companies dependent on specialized animal models.
Organ-on-chip systems, organoids, computational approaches, and other human-focused methods are gaining regulatory and research attention as alternatives or complements to animal studies. In 2025, India amended its drug-testing framework to explicitly allow organ-on-chip and related new-approach methods, while NIH announced greater emphasis on human-focused approaches. This shift can reduce the share of research budgets allocated to conventional animal models and pressure suppliers to diversify their offerings.
The mice segment accounted for a share of 48.7% in 2025 and is expected to grow at a CAGR of 9% during the forecast period 2026-2034, due to their well-established use in biomedical research, genetic similarity to humans, availability of standardized strains, and suitability for disease modeling, drug development, and preclinical studies.
The rat, guinea pig, rabbit, and other segments are also expected to support market growth through their applications in toxicology, immunology, infectious disease research, pharmaceutical testing, and specialized biomedical studies.
Request Customizationto receive a tailored report.
The drug discovery and development segment accounted for a share of 55.9% in 2025 and is expected to grow at a CAGR of 9.1% during the forecast period 2026-2034, owing to the extensive use of animal models for preclinical drug testing, safety and efficacy evaluation, disease modeling, and validation of therapeutic candidates, along with continued pharmaceutical research activities.
The basic research and other segments are also expected to support market growth through applications in disease studies, biological research, toxicology, and specialized experimental investigations.
The pharma and biotech companies segment accounted for a share of 58.6% in 2025 and is expected to grow at a CAGR of 9% during the forecast period 2026-2034, supported by extensive preclinical research activities, drug development programs, safety and efficacy testing, and the need for reliable animal models to evaluate therapeutic candidates.
The academic research institutes and other segments are also expected to support market growth through their use of animal models for basic research, disease studies, biological investigations, and specialized scientific research.
Speak to an Analystto discuss market opportunities.
The North American animal model market accounted for the largest regional share of 41.8% in 2025. The U.S. animal model market is expected to be influenced by the NIH’s planned investment of more than $150 million in 2026 to advance human-based research methods, which is reshaping the use of traditional animal models in biomedical research.
The U.S. animal model market is also supported by continued federal biomedical research funding and the development of alternative research methodologies, while the Canada animal model market is supported by $7 million in federal funding for 2026-2031 to strengthen animal-care standards and support the ethical use of animals in science.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe animal model market is expected to grow at a CAGR of 9.3% during the forecast period 2026-2034, showcasing the fastest-growing regional market. The European Commission’s latest available data show that first-time animal use in the EU and Norway fell to around 7.97 million in 2023, while regulatory testing use declined 35.1% from 2018, indicating a continued shift toward alternative research methods that is shaping the regional animal model landscape.
The U.K. animal model market is being influenced by a £22 million government initiative in 2026 to accelerate non-animal testing methods, including a £20 million preclinical translational models hub, while the Germany animal model market and France animal model market continue to benefit from strong biomedical research activity; France allocated €3.54 billion to life sciences research in 2025 and announced €45 million in additional France 2030 support for biomedical research institutes for 2026-2029.
The Asia Pacific animal model market accounted for a regional share of 21.4% in 2025. China’s 2026 biomedical innovation programs include dedicated funding of up to RMB 1 million per project for animal-model research and development, while South Korea’s proposed 2026 government R&D budget reached KRW 35.3 trillion, supporting broader life science and biomedical research activity.
The Japan animal model market is supported by FY2026 research programs covering basic, applied, and nonclinical/preclinical studies, including AMED’s e-ASIA health research program, while the China animal model market benefits from dedicated laboratory-animal and model-development programs; the South Korea animal model market is supported by increased government R&D investment, and the India animal model market is being shaped by continued expansion of biomedical research and research-infrastructure programs across the life-sciences ecosystem.
The animal model market is moderately fragmented, with specialized animal model developers, contract research organizations, laboratory-animal suppliers, biotechnology companies, and academic research providers competing across standard, genetically engineered, humanized, disease-specific, and patient-derived models. Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Inc., genOway S.A., and Janvier Labs are among the leading players in the animal model market, collectively accounting for an estimated 45-50% of the global animal model market share.
Established players compete primarily on model quality, genetic characterization, breeding capacity, biosecurity, reproducibility, regulatory support, and global distribution, while emerging players in the animal model market ecosystem compete through CRISPR-based model development, humanized models, specialized disease models, faster customization, and integrated preclinical services. The competitive landscape is also being shaped by the FDA’s 2025 initiative to reduce animal testing through AI-based computational models, cell-based methods, and organoid testing, increasing the importance of human-relevant model development and complementary research technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com